These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20605870)

  • 1. Inappropriate oral formulations and information in paediatric trials.
    Pandit S; Shah U; Kirby DJ; Nunn T; Tuleu C
    Arch Dis Child; 2010 Sep; 95(9):754-6. PubMed ID: 20605870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor formulation information in published pediatric drug trials.
    Standing JF; Khaki ZF; Wong IC
    Pediatrics; 2005 Oct; 116(4):e559-62. PubMed ID: 16199684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in availability of paediatric medicines in Australia between 1998 and 2002.
    Chui J; Tordoff J; Reith D
    Br J Clin Pharmacol; 2005 Jun; 59(6):736-42. PubMed ID: 15948941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
    Giacoia GP; Taylor-Zapata P; Zajicek A
    Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation of medicines for children.
    Nunn T; Williams J
    Br J Clin Pharmacol; 2005 Jun; 59(6):674-6. PubMed ID: 15948931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children.
    Orenstein SR; Gremse DA; Pantaleon CD; Kling DF; Rotenberg KS
    Clin Ther; 2005 Apr; 27(4):472-83. PubMed ID: 15922820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects.
    van Riet-Nales DA; Schobben AF; Vromans H; Egberts TC; Rademaker CM
    Arch Dis Child; 2016 Jul; 101(7):662-9. PubMed ID: 26979250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paediatric formulations--getting to the heart of the problem.
    Standing JF; Tuleu C
    Int J Pharm; 2005 Aug; 300(1-2):56-66. PubMed ID: 15979830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extemporaneous drug formulations.
    Nahata MC; Allen LV
    Clin Ther; 2008 Nov; 30(11):2112-9. PubMed ID: 19108799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific aspects of gastro-intestinal transit in children for drug delivery design.
    Bowles A; Keane J; Ernest T; Clapham D; Tuleu C
    Int J Pharm; 2010 Aug; 395(1-2):37-43. PubMed ID: 20478372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children's Acceptability of Oral Formulations (CALF) Study.
    Ranmal SR; Cram A; Tuleu C
    Int J Pharm; 2016 Nov; 514(1):296-307. PubMed ID: 27863675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulations and dosages of oral drugs.
    Calesnick B
    Am Fam Physician; 1978 Sep; 18(3):160-2. PubMed ID: 685796
    [No Abstract]   [Full Text] [Related]  

  • 14. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determination of drug posology in pediatrics].
    Autret E; Vasmant D
    Therapie; 1995; 50(4):381-6. PubMed ID: 7482393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of acceptability of oral paediatric medicines: a review.
    Mistry P; Batchelor H;
    J Pharm Pharmacol; 2017 Apr; 69(4):361-376. PubMed ID: 27524471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.
    Wu Y; Loper A; Landis E; Hettrick L; Novak L; Lynn K; Chen C; Thompson K; Higgins R; Batra U; Shelukar S; Kwei G; Storey D
    Int J Pharm; 2004 Nov; 285(1-2):135-46. PubMed ID: 15488686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population.
    Venables R; Batchelor H; Hodson J; Stirling H; Marriott J
    Int J Pharm; 2015 Mar; 480(1-2):55-62. PubMed ID: 25601436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained-release methylphenidate: new preparations. New pharmaceutical forms: a slight advantage for a small number of children.
    Prescrire Int; 2004 Dec; 13(74):203-6. PubMed ID: 15612099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration.
    Cole ET; Cadé D; Benameur H
    Adv Drug Deliv Rev; 2008 Mar; 60(6):747-56. PubMed ID: 18096270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.